Dapsone as a Current Option for the Treatment of Autoimmune Bullous Diseases with Autoimmunity to Non-Enzymes: A Retrospective Study from a Single Central European Referral Center
Abstract
:1. Introduction
2. Materials and Methods
- -
- Patients taking less than 10 mg/day of prednisolone equivalent prior to their initial DP dose, excluding those with absolute contraindications to GCSs;
- -
- Individuals with fewer than 10 active lesions (including blisters, erosions, or newly developed areas of erythema) before beginning DP therapy;
- -
- Subjects without follow-up data for a minimum of one year during DP treatment;
- -
- Patients who had been treated previously with immunosuppressants, rituximab (RTX), or intravenous immunoglobulin (IVIG);
- -
- Individuals with a history of allergic reactions to the prescribed medication.
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- van Beek, N.; Zillikens, D.; Schmidt, E. Diagnosis of autoimmune bullous diseases. J. Dtsch. Dermatol. Ges. 2018, 16, 1077–1091. [Google Scholar] [CrossRef]
- Bardazzi, F.; Loi, C.; Chessa Marco, A.; Di Altobrando, A.; Filippi, F.; Lacava, R.; Viviani, F.; Balestri, R.; Leuzzi, M.; Sacchelli, L. Therapeutic approaches and targets for treatment of autoimmune bullous diseases. Dermatol. Ther. 2021, 34, e15032. [Google Scholar] [CrossRef] [PubMed]
- Witte, M.; Zillikens, D.; Schmidt, E. Diagnosis of Autoimmune Blistering Diseases. Front. Med. 2018, 5, 296. [Google Scholar] [CrossRef] [PubMed]
- Saschenbrecker, S.; Karl, I.; Komorowski, L.; Probst, C.; Dähnrich, C.; Fechner, K.; Stöcker, W.; Schlumberger, W. Serological Diagnosis of Autoimmune Bullous Skin Diseases. Front. Immunol. 2019, 10, 1974. [Google Scholar] [CrossRef] [PubMed]
- Patsatsi, A.; Kokolios, M.; Kyriakou, A.; Lamprou, F.; Stylianidou, D.; Tsapas, A.; Goulis, D.G.; Murrell, D.F.; Sotiriadis, D. Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. Acta Derm. Venereol. 2017, 97, 1145–1147. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, E.; Goebeler, M.; Hertl, M.; Sárdy, M.; Sitaru, C.; Eming, R.; Hofmann, S.C.; Hunzelmann, N.; Kern, J.S.; Kramer, H. S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J. Dtsch. Dermatol. Ges. 2015, 13, 713–727. [Google Scholar] [CrossRef]
- Lee, M.S.; Yeh, Y.C.; Tu, Y.K.; Chan, T.C. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus. J. Am. Acad. Dermatol. 2021, 85, 176–186. [Google Scholar] [CrossRef] [PubMed]
- Żychowska, M.; Batycka-Baran, A.; Szepietowski, J.; Baran, W. Dapsone—Mechanism of action, safety of use and the role in the treatment of bullous pemphigoid according to current recommendations. Derm. Rev. 2016, 103, 176–184. [Google Scholar] [CrossRef]
- Khalilzadeh, M.; Shayan, M.; Jourian, S.; Rahimi, M.; Sheibani, M.; Dehpour, A.R. A comprehensive insight into the anti-inflammatory properties of dapsone. Arch. Pharmacol. 2022, 395, 1509–1523. [Google Scholar] [CrossRef]
- Żychowska, M. Dapsone: A forgotten and underestimated treatment option for bullous pemphigoid? Br. J. Dermatol. 2017, 177, 1156–1157. [Google Scholar] [CrossRef]
- Wozel, G.; Blasum, C. Dapsone in dermatology and beyond. Arch. Dermatol. Res. 2014, 306, 103–124. [Google Scholar] [CrossRef] [PubMed]
- Jałowska, M.; Gornowicz-Porowska, J.; Seraszek-Jaros, A.; Bowszyc-Dmochowska, M.; Kaczmarek, E.; Dmochowski, M. Conceptualization and Validation of an Innovative Direct Immunofluorescence Technique Utilizing Fluorescein Conjugate against IgG + IgG4 for Routinely Diagnosing Autoimmune Bullous Dermatoses. Cent. Eur. J. Immunol. 2021, 46, 183–190. [Google Scholar] [CrossRef]
- Cappellini, M.D.; Fiorelli, G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008, 371, 64–74. [Google Scholar] [CrossRef] [PubMed]
- Cisoń, H.; Białynicki-Birula, R.; Szepietowski, J. Czy należy oceniać aktywność dehydrogenazy glukozo-6-fosforanowej (G6PD) przed podaniem Dapsonu u każdego pacjenta, czy tylko w grupach ryzyka w populacji polskiej?/Should the activity of glucose-6-phosphate dehydrogenase (G6PD) be assessed before administering Dapsone in every patient or only in risk groups in Poland? Forum Dermatol. 2022, 8, 170. [Google Scholar]
- Murrell, D.F.; Dick, S.; Ahmed, A.R.; Amagai, M.; Barnadas, M.A.; Borradori, L.; Bystryn, J.C.; Cianchini, G.; Díaz, L.A.; Fivenson, D.P.; et al. Consensus Statement on Definitions of Disease, End Points, and Therapeutic Response for Pemphigus. J. Am. Acad. Dermatol. 2008, 58, 1043–1046. [Google Scholar] [CrossRef] [PubMed]
- Spałek, M.M.; Jałowska, M.; Bowszyc-Dmochowska, M.; Dmochowski, M. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center. Medicina 2024, 60, 270. [Google Scholar] [CrossRef]
- Spałek, M.M.; Bowszyc-Dmochowska, M.; Dmochowski, M. Intravenous Immunoglobulin for Autoimmune Bullous Diseases: A Case Series from a Central European Referral Center. Medicina 2023, 59, 1265. [Google Scholar] [CrossRef]
- Suda, T.; Suzuki, Y.; Matsui, T.; Inoue, T.; Niide, O.; Yoshimaru, T.; Suzuki, H.; Ra, C.; Ochiai, T. Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. Br. J. Dermatol. 2005, 152, 887–895. [Google Scholar] [CrossRef] [PubMed]
- Thuong-Nguyen, V.; Kadunce, D.P.; Hendrix, J.D.; Gammon, W.R.; Zone, J.J. Inhibition of neutrophil adherence to antibody by dapsone: A possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J. Investig. Dermatol. 1993, 100, 349–355. [Google Scholar] [CrossRef]
- Stendahl, O.; Molin, L.; Lindroth, M. Granulocyte-mediated release of histamine from mast cells: Effect of myeloperoxidase and its inhibition by antiinflammatory sulfone compounds. Int. Arch. Allergy Appl. Immunol. 1983, 70, 277–284. [Google Scholar] [CrossRef]
- Schmidt, E.; Reimer, S.; Kruse, N.; Bröcker, E.B.; Zillikens, D. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin. Exp. Immunol. 2001, 124, 157–162. [Google Scholar] [CrossRef] [PubMed]
- Abe, M.; Shimizu, A.; Yokoyama, Y.; Takeuchi, Y.; Ishikawa, O. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus. Clin. Exp. Dermatol. 2008, 33, 759–763. [Google Scholar] [CrossRef]
- Giordano, C.N.; Sinha, A.A. Cytokine networks in Pemphigus vulgaris: An integrated viewpoint. Autoimmunity 2012, 45, 427–439. [Google Scholar] [CrossRef]
- Liu, Y.; Wang, Y.; Chen, X.; Jin, H.; Li, L. Factors associated with the activity and severity of bullous pemphigoid: A review. Ann. Med. 2020, 52, 55–62. [Google Scholar] [CrossRef] [PubMed]
- Grando, S.A.; Glukhenky, B.T.; Drannik, G.N.; Epshtein, E.V.; Kostromin, A.P.; Korostash, T.A. Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch. Dermatol. 1989, 125, 925–930. [Google Scholar] [CrossRef]
- Bonney, R.J.; Wightman, P.D.; Dahlgren, M.E.; Sadowski, S.J.; Davies, P.; Jensen, N.; Lanza, T.; Humes, J.L. Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biochem. Pharmacol. 1983, 32, 361–366. [Google Scholar] [CrossRef] [PubMed]
- Berlow, B.A.; Liebhaber, M.I.; Dyer, Z.; Spiegel, T.M. The effect of dapsone in steroid-dependent asthma. J. Allergy Clin. Immunol. 1991, 87, 710–715. [Google Scholar] [CrossRef] [PubMed]
- Murthy, S.; Schilf, P.; Patzelt, S.; Thieme, M.; Becker, M.; Kröger, L.; Bremer, T.; Derenda-Hell, A.; Knebel, L.; Fagiani, F.; et al. Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases. J. Investig. Dermatol. 2021, 141, 2587–2595.e2. [Google Scholar] [CrossRef]
- Rosenberg, F.R.; Sanders, S.; Nelson, C.T. Pemphigus: A 20-year review of 107 patients treated with corticosteroids. Arch. Dermatol. 1976, 112, 962–970. [Google Scholar] [CrossRef]
- Piamphongsant, T. Pemphigus controlled by dapsone. Br. J. Dermatol. 1976, 94, 681–686. [Google Scholar] [CrossRef]
- Haim, S.; Friedman-Birnbaum, R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978, 156, 120–123. [Google Scholar] [CrossRef]
- Werth, V.P.; Fivenson, D.; Pandya, A.G.; Chen, D.; Rico, M.J.; Albrecht, J.; Jacobus, D. Multicenter Randomized, Double-blind, Placebo-Controlled, Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance-Phase Pemphigus Vulgaris. Arch. Dermatol. 2008, 144, 25–32. [Google Scholar] [CrossRef]
- Almugairen, N.; Hospital, V.; Bedane, C.; Duvert-Lehembre, S.; Picard, D.; Tronquoy, A.F.; Houivet, E.; D’incan, M.; Joly, P. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J. Am. Acad. Dermatol. 2013, 69, 583–588. [Google Scholar] [CrossRef] [PubMed]
- Baum, S.; Debby, A.; Gilboa, S.; Trau, H.; Barzilai, A. Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study. Dermatology 2016, 232, 578–585. [Google Scholar] [CrossRef] [PubMed]
- Mocanu, M.; Procopciuc, D.; Gheucă-Solovăstru, D.-F.; Popescu, I.A.; Olinici, D.T.; Pătrașcu, A.I.; Vâță, D.; Gheucă-Solovăstru, L. An Overview of Methotrexate Indications in Skin Diseases. Medicina 2024, 60, 1024. [Google Scholar] [CrossRef]
- Jain, K.; Thakur, V.; Handa, S.; Thakur, N.; Shilpa; Sachdeva, N.; Mahajan, R.; De, D. A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris. Sci. Rep. 2022, 12, 7525. [Google Scholar] [CrossRef]
- Ishii, N.; Maeyama, Y.; Karashima, T.; Nakama, T.; Kusuhara, M.; Yasumoto, S.; Hashimoto, T. A clinical study of patients with pemphigus vulgaris and pemphigus foliaceous: An 11-year retrospective study (1996–2006). Clin. Exp. Dermatol. 2008, 33, 641–643. [Google Scholar] [CrossRef]
- Gurcan, H.M.; Ahmed, A.R. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: Analysis of current data. Am. J. Clin. Dermatol. 2009, 10, 383–396. [Google Scholar] [CrossRef] [PubMed]
- Borradori, L.; Van Beek, N.; Feliciani, C.; Tedbirt, B.; Antiga, E.; Bergman, R.; Böckle, B.C.; Caproni, M.; Caux, F.; Chandran, N.S.; et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J. Eur. Acad. Dermatol. Venereol. 2022, 36, 1689–1704. [Google Scholar] [CrossRef]
- Schmidt, E.; Rashid, H.; Marzano, A.V.; Lamberts, A.; Di Zenzo, G.; Diercks, G.F.H.; Alberti-Violetti, S.; Barry, R.J.; Borradori, L.; Caproni, M.; et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology—Part II. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 1926–1948. [Google Scholar] [CrossRef]
- Hofmann, S.C.; Kautz, O.; Hertl, M.; Sticherling, M.; Zillikens, D.; Bruckner-Tuderman, L. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J. Dtsch. Dermatol. Ges. 2009, 7, 227–233, English, German. [Google Scholar] [CrossRef] [PubMed]
- Esmaili, N.; Hallaji, Z.; Soori, T.; Davatchi, C.C. Bullous pemphigoid in Iranian patients: A descriptive study on 122 cases. Acta Med. Iran 2012, 50, 335–338. [Google Scholar] [PubMed]
- Kibsgaard, L.; Bay, B.; Deleuran, M.; Vestergaard, C. A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre. Acta Derm. Venereol. 2015, 95, 307–311. [Google Scholar] [CrossRef] [PubMed]
- Piamphongsant, T. Dapsone for the treatment of bullous pemphigoid. Asian Pac. J. Allergy Immunol. 1983, 1, 19–21. [Google Scholar]
- Venning, V.A.; Millard, P.R.; Wojnarowska, F. Dapsone as the first line treatment for bullous pemphigoid. Br. J. Dermatol. 1989, 120, 83–92. [Google Scholar] [CrossRef]
- Person, J.R.; Rogers, R.S. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch. Dermatol. 1977, 113, 610–615. [Google Scholar] [CrossRef]
- Bouscarat, F.; Chosidow, O.; Picard-Dahan, C.; Sakizm, V.; Crickx, B.; Prost, C.; Roujeau, J.C.; Revuz, J.; Belaich, S. Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six case. J. Am. Acad. Dermatol. 1996, 34, 683–684. [Google Scholar] [CrossRef]
- Tirado-Sánchez, A.; Díaz-Molina, V.; Ponce-Olivera, R.M. Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid. Allergol. Immunopathol. 2012, 40, 152–155. [Google Scholar] [CrossRef] [PubMed]
- Sticherling, M.; Franke, A.; Aberer, E.; Gläser, R.; Hertl, M.; Pfeiffer, C.; Rzany, B.; Schneider, S.; Shimanovich, I.; Werfel, T.; et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br. J. Dermatol. 2017, 177, 1299–1305. [Google Scholar] [CrossRef]
- Staines, K.; Hampton, P.J. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: A case series. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012, 114, e49–e56. [Google Scholar] [CrossRef]
- Johnson, K.B.; Rosenbaum, J.T.; Yarter, J.T.; Broadbent, T.; Michels, K.S. A 10-Year Review of the Management of Ocular Mucous Membrane Pemphigoid: A Private Practice Experience. Cornea 2023, 42, 565–571. [Google Scholar] [CrossRef] [PubMed]
- Ezhilarasan, D. Dapsone-induced hepatic complications: It’s time to think beyond methemoglobinemia. Drug Chem. Toxicol. 2021, 44, 330–333. [Google Scholar] [CrossRef]
- Shukkoor, A.A.; Thangavelu, S.; George, N.E.; Priya, S. Dapsone Hypersensitivity Syndrome (DHS): A Detrimental Effect of Dapsone? A Case Report. Curr. Drug. Saf. 2019, 14, 37–39. [Google Scholar] [CrossRef]
- Bartakke, S.P.; Sampagar, A.A.; Reddy, N.A.; Kangle, R. Dapsone Induced Agranulocytosis and Hemolytic Anemia in Immune Thrombocytopenic Purpura. Indian J. Pediatr. 2020, 87, 856. [Google Scholar] [CrossRef] [PubMed]
- Pahadiya, H.R.; Lakhotia, M. Dapsone Hypersensitivity Syndrome with Leukemoid Reaction and Severe Thrombocytosis. Cureus 2021, 13, e14026. [Google Scholar] [CrossRef]
- Coleman, M.D. Dapsone: Modes of action, toxicity and possible strategies for increasing patient tolerance. Br. J. Dermatol. 1993, 129, 507–513. [Google Scholar] [CrossRef]
- Coleman, M.D. Dapsone-mediated agranulocytosis: Risks, possible mechanisms and prevention. Toxicology 2001, 162, 53–60. [Google Scholar] [CrossRef]
- Rieder, M.J.; Uetrecht, J.; Shear, N.H.; Cannon, M.; Miller, M.; Spielberg, S.P. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro “rechallenge” with hydroxylamine metabolites. Ann. Intern. Med. 1989, 110, 286–289. [Google Scholar] [CrossRef]
- Liu, H.; Wang, Z.; Bao, F.; Wang, C.; Sun, L.; Zhang, H.; Yu, G.; Mi, Z.; Li, J.; Li, L.; et al. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients with Leprosy. JAMA Dermatol. 2019, 155, 666–672. [Google Scholar] [CrossRef]
- Zhang, F.R.; Liu, H.; Irwanto, A.; Fu, X.A.; Li, Y.; Yu, G.Q.; Yu, Y.X.; Chen, M.F.; Low, H.Q.; Li, J.H.; et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med. 2013, 369, 1620–1628. [Google Scholar] [CrossRef] [PubMed]
Disease Type | Number of Patients | Number of Women (Percentage) | Age (Years) | Baseline Prednisone Equivalent Dosage (mg) |
---|---|---|---|---|
PV | 19 | 63.16 | 55.11 ± 12.76 | 26.11 ± 12.97 |
PF | 9 | 55.56 | 60.89 ± 10.83 | 24.29 ± 14.74 |
MMP | 9 | 44.44 | 73.89 ± 8.43 | 22.5 ± 4.33 |
BP | 4 | 25 | 71.25 ± 4.44 | 23.75 ± 9.92 |
Disease Type | Number of Patients | AH | T2DM | HF | COPD | HT |
---|---|---|---|---|---|---|
PV | 19 | 26.32 | 15.79 | 5.26 | 5.26 | 31.58 |
PF | 9 | 33.33 | 22.22 | 0 | 11.11 | 33.33 |
MMP | 9 | 33.33 | 33.33 | 22.22 | 22.22 | 22.22 |
BP | 4 | 75 | 50 | 25 | 25 | 25 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Spałek, M.M.; Jałowska, M.; Welc, N.; Bowszyc-Dmochowska, M.; Dmochowski, M. Dapsone as a Current Option for the Treatment of Autoimmune Bullous Diseases with Autoimmunity to Non-Enzymes: A Retrospective Study from a Single Central European Referral Center. Medicina 2024, 60, 1324. https://doi.org/10.3390/medicina60081324
Spałek MM, Jałowska M, Welc N, Bowszyc-Dmochowska M, Dmochowski M. Dapsone as a Current Option for the Treatment of Autoimmune Bullous Diseases with Autoimmunity to Non-Enzymes: A Retrospective Study from a Single Central European Referral Center. Medicina. 2024; 60(8):1324. https://doi.org/10.3390/medicina60081324
Chicago/Turabian StyleSpałek, Maciej Marek, Magdalena Jałowska, Natalia Welc, Monika Bowszyc-Dmochowska, and Marian Dmochowski. 2024. "Dapsone as a Current Option for the Treatment of Autoimmune Bullous Diseases with Autoimmunity to Non-Enzymes: A Retrospective Study from a Single Central European Referral Center" Medicina 60, no. 8: 1324. https://doi.org/10.3390/medicina60081324